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Abstract
Background: Persistent hypercapnia after COPD exacerbation is associated with excess mortality and early
rehospitalization. High Flow Nasal cannula (HFNC), may be theoretically an alternative to long-term noninvasive
ventilation (NIV), since physiological studies have shown a reduction in PaCO2 level after few hours of treatment.
In this clinical study we assessed the acceptability of HFNC and its effectiveness in reducing the level of PaCO2 in
patients recovering from an Acute Hypercapnic Respiratory Failure (AHRF) episode. We also hypothesized that the
response in CO2 clearance is dependent on baseline level of hypercapnia.
Methods: Fifty COPD patients recovering from an acute exacerbation and with persistent hypercapnia, despite
having attained a stable pH (i.e. pH > 7,35 and PaCO2 > 45 mmHg on 3 consecutive measurements), were enrolled
and treated with HFNC for at least 8 h/day and during the nighttime
Results: HFNC was well tolerated with a global tolerance score of 4.0 ± 0.9. When patients were separated into
groups with or without COPD/OSA overlap syndrome, the “pure” COPD patients showed a statistically significant
response in terms of PaCO2 decrease (p = 0.044). In addition, the subset of patients with a lower pH at enrolment
were those who responded best in terms of CO2 clearance (score test for trend of odds, p = 0.0038).
Conclusions: HFNC is able to significantly decrease the level of PaCO2 after 72 h only in “pure” COPD patients,
recovering from AHRF. No effects in terms of CO2 reduction were found in those with overlap syndrome. The
present findings will help guide selection of the best target population and allow a sample size calculation for
future long-term randomized control trials of HFNC vs NIV.
Trial registration: This study is registered with www. clinicaltrials.gov with identifier number NCT03759457.
Keywords: Chronic obstructive pulmonary disease, High flow nasal cannula, Persistent hypercapnia, Long term non
invasive ventilation
© The Author(s). 2020 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: lara.pisani@aosp.bo.it
1Respiratory and Critical Care Unit, University Hospital St. Orsola-Malpighi, Via
G. Massarenti 9, Pavilion 15, Bologna, Italy
Full list of author information is available at the end of the article
Pisani et al. BMC Pulmonary Medicine           (2020) 20:12 
https://doi.org/10.1186/s12890-020-1048-7
Background
A number of observational studies have reported increased
mortality associated with chronic hypercapnia in patients
with Chronic Obstructive Pulmonary Disease (COPD) [1, 2].
For this reason, long-term noninvasive ventilation (NIV) has
been suggested as a strategy to decrease the PaCO2 levels,
with a few investigations demonstrating an improvement in
survival and/or exacerbation rates [3–5].
High levels of inspiratory pressure are usually applied
in an attempt to maximally reduce PaCO2 [4, 5], but this
approach may be not well tolerated in all the patients.
An alternative method to reduce hypercapnia is the use
of high flow nasal cannula (HFNC). Physiological short
term studies have shown that HFNC can generate an acute
reduction of PaCO2 [6–8], even over a wide variation of
different baseline PaCO2 levels (from as low as 1.3mmHg
for a PaCO2 of 38.4mmHg (− 3%) to 6.4mmHg for a
PaCO2 of 61.2mmHg (− 9.2%). When compared to NIV,
HFNC also demonstrated a similar reduction of inspiratory
muscle effort, compared to spontaneous breathing [7].
HFNC therapy is reported to improve patient comfort
[9–12], avoid mucosal dryness and injury [13–15], and
deliver a more reliable and stable fraction of inspired
oxygen (FiO2) [13, 16].
One investigation with 11 COPD patients [17] treated
for 6 weeks of home HFNC, showed a significant and
impressive reduction in PaCO2 compared to baseline (>
8 mmHg). However, this study had a small sample size,
relied on the recording of arterialized PaCO2 measure-
ments, and used a relatively low fixed flow of 20 L/min,
that has been shown to have a lower CO2 clearance than
studies using higher flow rates [17].
A randomized cross-over study in stable hypercapnic
COPD patients on long-term oxygen therapy (LTOT) dem-
onstrated that the addition of HFNC was able to improve
health-related Quality of Life (QoL) and reduce hypercapnia
in these patients [18]. However, the participants in this trial
were atypical of most patients with severe COPD, since 37%
were stage GOLD II and III and had comparatively low
exacerbation and hospital admission rates, which may limit
the clinical applicability of these findings [18]. Recently, it
has been demonstrated that HFNC treatment reduced acute
exacerbations, hospital admissions and symptoms in COPD
patients with hypoxic failure [19]. This highlights the need
for future randomised trials comparing HFNC vs NIV.
In fact, for patients with persistent hypercapnia follow-
ing an acute life-threatening exacerbation of COPD,
Murphy et al. [5] showed that the addition of home NIV
to home oxygen therapy prolonged the time to readmis-
sion or death over a 12-month period.
In the current investigation, the goal was to assess the
acceptability of HFNC and its effectiveness in reducing
the level of PaCO2. The longer term research goal, based
on previous physiological studies, is to demonstrate that
the response of COPD patients with persistent hypercapnia
after an acute exacerbation to HFNC is dependent on their
baseline level of hypercapnia. This current study will help
guide selection of the best target population and allow a
sample size calculation for future long-term randomized
control trials (RCTs) of HFNC vs NIV.MATERIAL and
METHODSFifty COPD patients recovering from an acute
exacerbation requiring hospital admission and with persist-
ent hypercapnia, despite having attained a stable pH (i.e.
pH > 7,35 and PaCO2 > 45mmHg on 3 consecutive mea-
surements), were enrolled in this interventional study. The
protocol was approved by our local ethical committee and
written informed consent was obtained from each patient.
This study is registered with www. clinicaltrials.gov with
identifier number NCT03759457.
Documented or highly suspected OSA/COPD overlap
syndrome was not considered an exclusion criteria and was
defined as the presence of 15 or more obstructive respira-
tory events per hour of sleep, when a previous full night
polysomnography (PSG) was available (n.12 patients) [20]
or from a positive Epworth questionnaire and a Body Mass
Index (BMI) > 25 (n.11 patients) [21].
Cardiac decompensation, restrictive thoracic disorders,
renal insufficiency, cancer, and neurological disease were
considered exclusion criteria.
On day 1 the patients underwent a preliminary trial
with HFNC to set the optimal flow, using the AIRVO 2
(Fisher & Paykel Healthcare, Auckland, New Zealand).
The patients were asked to breathe while trying to keep
their mouth closed at flow rates from 20 L/min up to 40
L/min for a minimum of 15min, if tolerated, for each
trial. At the end of this test, the maximum level tolerated
for 15 min was chosen as the flow to be used for the ex-
perimental procedure. Temperature was set according to
the patient’s tolerance starting from 31 °C, up to 37 °C,
while FiO2 was adjusted to maintain an SaO2 between
92 and 94%.
Between 9 am of day 2 and 9 am of day 5 (72 h period), pa-
tients underwent HFNC for at least 8 h/day plus during the
nighttime. The nurse on shift was in charge of supervising
the adherence to this schedule and to record any protocol
violations on a dedicated sheet. Recorded every morning at
10 am were: Arterial Blood Gases (ABGs) performed without
HFNC, effective hours of HFNC and therapy tolerance, as
measured through patient self -reporting using the following
scale: 1. very bad, 2. bad, 3. moderate, 4. good, and 5. very
good.
Statistical analysis
Data are presented as a mean and standard deviation
(SD). We used Repeated Measures Analysis of Variance
to analyse the ABGs changes and the tolerance to HFNC
during the trial. Repeated Measures Analysis of Variance
were used to determine the difference between overlap
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syndrome COPD patients and “pure” COPD patients,
without overlap syndrome. Post-hoc pairwise comparisons
were performed with pairwise Bonferroni’s method. A
test for linear trend of the odds was used to compare the
baseline PaCO2 levels against the changes in PaCO2 after
48 h and pH values at baseline.
We considered two-sided p values less than 0.05 to be
statistically significant. Statistical analysis was performed
with Stata/Se 14.2 software (StataCorp, College Station
TX, USA).
Results
Table 1 shows the clinical characteristics of the patients.
None of the patients were on a home care ventilator
program, either due to having previously refused NIV or
because they did not meet the enrolment criteria estab-
lished in our unit (i.e. PaCO2 > 55 mmHg). All were
naive to HFNC therapy. 12/50 patients were affected by
overlap syndrome.
The protocol was well tolerated by all but one of the
patients without major discomfort or any change in the
time course of the experiment with regards to flow,
temperature and FiO2. The mean flow applied was
33.5 ± 3.2 L/min. The exception was one patient found
the warm temperature uncomfortable. HFNC was well
tolerated with a global tolerance score of 4.0 ± 0.9. The
mean usage of HFNC was 64.5 ± 10.5 h.
Overall, 70% of patients (35/50) received NIV prior to
HFNC, most of these patients were “pure” COPD (25/
35). Table 2 shows key patient characteristics according
to blood gases during exacerbation and the time interval
between treatments.
Figure 1 is a plot of the time course of PaCO2 during
the trial. Although a positive trend of PaCO2 reduction
was observed, no significant differences were found
among the trial in all patients. However, a statistically
significant reduction in respiratory rate was observed at
48 h (Fig. 2).
Table 3 summarizes the ABG values; no statistically
significant differences were found in terms of pH,
HCO3− and PaO2/FiO2 ratio changes during the trial.
On the other hand, when the patients were separated
into groups with or without COPD/OSA overlap syn-
drome, the “pure” COPD patients showed a statistically
significant response in terms of PaCO2 decrease (p =
0.044). The comparison of trends of PaCO2 among
COPD patients and subjects with overlap syndrome is
shown in Fig. 3.
The patients were divided into two groups: those for
whom a reduction of PaCO2 from baseline to 48 h occurred
(Group A) and those for whom PaCO2 either increased or
changed “minimally” (− 2%) (Group B). When comparing
the two groups, it was found that patients with a lower pH
were more likely to respond to HFNC (Fig. 4, Table 4, score
test for trend of odds, p = 0.0038).
Discussion
In this study performed in patients with persistent hyper-
capnia after an episode of AHRF, we have shown for the
first time that while HFNC is able to significantly decrease
the level of PaCO2 after 72 h in “pure” COPD patients, this
was not the case for those with overlap syndrome. In
addition, the subset of patients with a lower pH at enrol-
ment were those who responded best in terms of CO2
clearance. This study highlights the need for an RCT com-
paring the long term effects of NIV vs HFNC, in the cluster
of patients more likely to respond to HFNC.
Table 1 Demographic data of all patients
n = 50
Age, yrs 75,7 ± 9,3
Sex (M/F) 16/34
BMI 26 ± 6
FEV1 (% pred) 42,1 ± 17,4
LTOT (n/total) 27/50
History of mechanical ventilation (n/total) 26/50
“Acute” NIV during exacerbation
(n/total)
35/50
Actual Smokers (n/total) 10/50
Ex-Smokers (n/total) 25/50
Charlson Index 6,4 ± 2,0
pH 7.41 ± 0.06
PaCO2 (mmHg) 60 ± 1.4
PaO2/FiO2 200.5 ± 8.7
HCO3- (mmol/L) 35.3 ± 1.03
Respiratory rate (b/min) 22.02 ± 0.6
Data are presented as mean ± SD
NIV Non invasive ventilation, BMI Body Mass Index, FEV1 Forced Expiratory
Volume in the 1st second, LTOT Long Term Oxygen Therapy
Table 2 Blood gases values during acute exacerbation and time
interval between treatments
Patients (n = 50)
pH 7.30 ± 0.05
PaCO2 (mmHg) 79.1 ± 13.7
Time interval between onset
of the exacerbation and HFNC
beginning (hours)
88.8 ± 40
Time interval between NIV
treatment and the onset of
HFNC (hours)
49.8 ± 15
Data are presented as mean ± SD
NIV Non invasive ventilation, HFNC High flow nasal cannula
Data are presented as mean ± SD
NIV Non invasive ventilation, BMI Body Mass Index, FEV1 Forced Expiratory
Volume in the 1st second, LTOT Long Term Oxygen Therapy
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Several short-term physiological studies (a maximum of
2 h total test time) [6, 7] have shown that HFNC can im-
prove some relevant physiological parameters, including de-
creasing the level of hypercapnia, in stable COPD patients.
A randomized controlled study comparing HFNC with
“standard” oxygen demonstrated that the former was
able to significantly reduce PaCO2, while improving
quality of life [18].
Recently, Storgaard and colleagues [19] in a large sized
study randomized 200 COPD patients with chronic hypox-
emic respiratory failure to long term oxygen therapy (LTOT)
or LTOT plus HFNC home treatment for 12months. This
study showed that the long-term HFNC treatment signifi-
cantly reduces acute exacerbations, hospitalization and
PaCO2 levels, therefore suggesting that HFNC may be an
alternative to home NIV for some COPD patients [19].
Fig. 1 Changes in mean PaCO2 level during the trial in all patients
Fig. 2 Respiratory rate during the trial
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As the physiological mechanisms of NIV and HFNC
treatments are quite different, it is important to better
understand which subset of patients are more likely to
benefit from HFNC long-term application.
For example, NIV is likely to correct the mechanism
leading to hypercapnia through increasing alveolar ventila-
tion, by augmenting tidal volume while reducing respira-
tory rate, and reducing CO2 production by decreasing the
work of breathing [22–24]. HFNC on the other hand may
also increase tidal volume and reduce the inspiratory ef-
fort [6–8], although to a lesser extent than NIV [7], but
may have additional physiological mechanisms [25].
For example, HFNC improves the lung mucociliary
clearance [13–15], the washout of upper airway dead
space [26–29], and generates a low level of positive air-
way pressure (PEEP effect) [16, 30–32], together with a
decrease in inspiratory resistance and an increase in expira-
tory resistance [13, 33].
NIV has been suggested to decrease the number of
exacerbations per year and also mortality in two differ-
ent groups of COPD patients, either in a phase of clin-
ical stability or with persistent hypercapnia after an
episode of AHRF [5]. The approach used in the second
patient group was probably reported to be more “ac-
cepted” and tolerated, since the drop out and non-
compliant rate was about 40% in the patients enrolled
when already stable vs 10% of those enrolled a few days
after the hospital discharge [5].
For this reason, we decided to study the effect of
HFNC in the latter cluster of patients.
We have shown for the first time that patients with a
combination of COPD and sleep apnea (i.e. overlap syn-
drome) are not likely to benefit from HFNC treatment.
Most of the previous clinical and physiological studies did
not exclude a priori these subjects.
Few investigations assessed the effects of HFNC during
sleep, showing that while breathing pattern response to
HFNC depends on the wake/sleep state in normal
healthy adults, it varies widely during wakefulness in pa-
tients with COPD [34, 35].
Indeed it was shown that during sleep these patients
have a more rapid shallow breathing pattern using
HFNC, compared with that of the control group on
standard oxygen, but on the other hand they decreased
PaCO2, as well as Work of Breathing, indicating a better
alveolar ventilation [34, 35].
The authors of the latter study concluded that HFNC
may be used during sleep as an alternative means to as-
sist ventilation in patients prone to develop respiratory
failure due to increased respiratory loads or insufficient
alveolar ventilation [34].
Unfortunately, the patients enrolled were not likely to
be affected by sleep disturbancies, as demonstrated by
the low Respiratory Disturbance Index (RDI) and by the
absence of relevant desaturations [34].
Despite the favourable results of the Biselli study [34],
it is likely, as demonstrated in our study, that the effects
of HFNC are not sufficient in overlap syndrome patients
to fully relieve the increased mechanical load imposed
by hyperinflation on poorly functioning respiratory mus-
cles. NIV normalizes nocturnal hypoxemia, enhances the
Table 3 ABG values during the trial
baseline 24 h 48 h 72 h
pH 7.41 ± 0.006 7.42 ± 0.006 7.42 ± 0.006 7.43 ± 0.007
PaCO2 (mmHg) 60 ± 1.41 59.7 ± 1.43 59.4 ± 1.46 56.7 ± 1.7
PaO2/FiO2 200.5 ± 61 196.4 ± 58 208 ± 63 200.2 ± 66
HCO3− (mmol/L) 35.3 ± 1.03 36.7 ± 1.04 36.6 ± 1.06 35.3 ± 1.2
Data are presented as mean ± SD
Fig. 3 Trend of PaCO2 values during the trial according the presence or not of COPD/OSA overlap syndrome. *72 h vs baseline:
p = 0.044(Bonferroni-adjusted p-values)
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quality of sleep, and may even restore the hyporespon-
siveness to CO2 [36, 37]. In addition, treatment with
continuous positive airway pressure (CPAP) significantly
reduces mortality and severe COPD exacerbations lead-
ing to hospitalization that have been shown to occur in
these patients [38].
The present study largely confirms the data obtained
with COPD patients with a pH in the normal range,
whether clinically stable or recovering from an AHRF
episode, showing that HFNC may be efficient in redu-
cing PaCO2 and respiratory rate [6, 7, 17, 18].
In patients with hypercapnic respiratory failure, HFNC
use for 6 weeks led to a decrease in capillary pCO2 [17]
and similar results were obtained in a short term study
showing not only a reduction in PaCO2 but also in oxy-
gen consumption [39].
Similar changes in PaCO2 were described in another
investigation where HFNC led to a flow-dependent
reduction in PaCO2, with values becoming close to nor-
mocapnia, accompanied by an increase in Tidal Volume
(TV) and a decrease in minute volume, resulting in a
reduction of the rapid shallow breathing index, an indi-
cator of respiratory work load [40].
In a randomised controlled physiological crossover
study, Fraser et al. [6] assessed the short-term response
to HFNC therapy (30 L/min) vs conventional oxygen
therapy in 30 patients. HFNC decreased transcutaneous
CO2, inspiration to expiration ratio and respiratory rate,
with a concurrent increase in End Expiratory Lung Vol-
ume and TV compared with LTOT.
In a second similar study, Pisani et al. [7] studied the
effects of HFNC versus NIV on inspiratory effort in
fourteen patients with hypercapnic COPD, by measuring
transdiaphragmatic pressure, breathing pattern and gas
exchange. HFNC and NIV were both able to significantly
improve breathing pattern and reduce inspiratory effort
when compared to standard oxygen; however, arterial
carbon dioxide oxygen tension decreased, but not
Fig. 4 Frequency distribution of Groups A and B according to ranges of pH values. Patients were divided into two groups: those for whom a
reduction of PaCO2 from baseline to 48 h occurred (Group A) and those for whom PaCO2 either increased or changed “minimally” (− 2%) (Group
B). This figure shows the frequency distribution of each group according to ranges of pH values
Table 4 Score test for trend of odds between Groups A and B
according to ranges of pH values
pH ranges Group B Group A Odds [95% Conf. Interval]
7.35–7.37 3 7 0.42857 0.11083 -1.65733
7.38–7.39 1 5 0.20000 0.02337 - 1.71188
7.40–7.41 4 6 0.66667 0.18813 - 2.36242
7.42–7.43 6 3 2.00000 0.50020 -7.99688
7.44–7.45 4 1 4.00000 0.44708 -35.78757
≥7.46 7 2 3.50000 0.72709 -16.84797
Score test for trend of odds: p = 0.0038
Patients were divided into two groups: those for whom a reduction of PaCO2
from baseline to 48 h occurred (Group A) and those for whom PaCO2 either
increased or changed “minimally” (− 2%) (Group B). This table shows the Score
test for trend of odds between the two groups according to ranges of
pH values
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significantly [7]. Several mechanisms are involved in the
explanation of these results [7, 25], such as the reduction
of inspiratory resistance and anatomical dead space in
the upper airways as well as the down-regulation of cold
receptors or osmoreceptors in the nasal mucosa. The
prolonged expiratory time may also reduce the amount
of PEEPi, which may be the source of increased inspira-
tory load, while increasing the end-expiratory and tidal
volumes, and decrease the respiratory rate [7, 25].
This study therefore highlights the potential of using
HFNC as alternative to NIV in COPD patient with
chronic hypercapnic patients.
The “exact” moment to start NIV in these patients is,
however, still controversial. In Köhnlein’s study [4] NIV
was initiated a relatively long time after an acute episode
of exacerbation, but despite the favourable results, the
drop out and/or compliance rate was suboptimal, while
in another RCT [5], showing similar results, NIV was
started after an episode of AHRF requiring NIV treat-
ment and the compliance rate was much better overall.
As already stated, all the studies using HFNC were
performed a relatively long time after an episode of
AHRF, and in patients not very likely to be ideal candi-
dates for long-term NIV, because of the level of hyper-
capnia, their severity stage and the number of previous
exacerbations. Therefore these results should not be
considered when designing a RCT, with a head-to-head
comparison between NIV and HFNC in patients likely
to benefit more from long term NIV.
Interestingly enough our results also showed that in
this subset of patients, the greatest PaCO2 reduction was
observed mainly in patients with lower pH, despite being
in the normal range.
Our study has some limitations. First of all, not all the
patients with overlap syndrome performed a full night
polysomnography, but obviously their medical history,
BMI and Epworth questionnaire suggested a likely com-
bination between COPD and sleep apnea syndrome. Sec-
ondly, one may argue that the mean flow rate applied
(33 L/min), may be suboptimal to obtain a maximized
CO2 clearance [41]. However, the flow employed in this
study was based on the patient’s tolerance, which is the
key to success when proposing a long-term chronic
application.
Finally, the study was performed in the recovery phase
of acute COPD exacerbation, that means the patients
might be still in the process of PaCO2 reduction, espe-
cially in the subset of patients with a lower pH at enrol-
ment [42]. Therefore, it is difficult to attribute the CO2
reducing effect to HFNC alone without a control group.
However, the hypothesis tested in this study is still legit-
imate as the fact that home NIV and long term oxygen
therapy (LTOT) has less physiological and clinical effect
in patients with the reversible hypercapnic phenotype
[42, 43]. In addition, in this “proof of concept” study, we
wanted to show that HFNC is able to reduce PaCO2 not
only in the stable phase, as already shown, but also after
an acute exacerbation, that is nowadays the “ideal” target
for starting home NIV, as suggested by the recent European
Respiratory Society guidelines on long-term home non-
invasive ventilation [44].
Conclusions
In conclusion we have shown that in COPD patients
recovering from an episode of AHRF, which have reached
a normal pH, the use of HFNC was associated with a sta-
tistically significant reduction in PaCO2 and respiratory
rate. The better response was obtained in the subset of
individuals with a lower pH level. This was not the case
for COPD patients with the overlap syndrome. The results
of this study may be useful to determine the sample size
and the “ideal” characteristics of patients to include in an
RCT aimed at assessing the efficacy of HFNC vs NIV in
COPD patients recovering from an episode of AHRF.
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